Our mission is to improve access and treatment for patients with OUD, and as we look back on 2023, we’re reflecting on what that really entails. This year, helping people meant…
…Helping the most vulnerable populations access treatment.
We expanded our insurance coverage while continuing to focus on Medicaid patients — a historically underserved group that faces many hurdles to accessing high-quality OUD treatment. And we launched partnerships with local organizations such as New York MATTERS (a statewide addiction referral network) to reach more people who struggle to find care.
…Being recognized for our role in changing the future of healthcare.
Our CEO Zack Gray was named to Business Insider's "30 Leaders Under 40 Changing Healthcare in 2023” as well as Slice of Healthcare’s “50 Under 50 awards” and Becker’s Emerging Leaders “37 Healthcare Company Leaders Under 40.”
…Earning the trust of 1,000+ Google reviewers.
Our 4.9 average rating is more than a number — it’s a sign that we're making such a meaningful difference in our patients’ lives that they want to tell others about it.
…Building the workforce to combat the opioid crisis.
We launched live, virtual buprenorphine trainings in partnership with the American Academy of Addiction Psychiatry — and saw them sell out.
…Publishing our own peer-reviewed research.
Our study with over 3,000 patients was published in JAMA, Journal of the American Medical Association Health Forum, showing that urine drug testing in a remote-care environment is highly feasible — further adding to the evidence that telehealth works.
…Getting the message out to more patients and loved ones.
We launched our first-ever TV commercial, ensuring that people have even more opportunities to learn about Ophelia from right where they are (in this case: their couch). Our F*ck Rehab campaign, launched at the beginning of the year, won gold in Purpose-Led Campaign of the year in the Healthcare Marketing Impact awards.
…Advocating for our patients with the DEA.
When the DEA approached a decision about remote prescribing rules for OUD patients, we were relentless with our advocacy, which included participating in the agency’s Listening Sessions. (The result? The DEA indeed listened, and extended its flexible telemedicine prescribing.)
…Having a seat at the table during policy events.
At the ATA’s Telehealth Awareness Week in DC this September, we were there to meet with legislators whose influence is vital for ensuring that telemedicine continues to impact access and outcomes for those with OUD.
…Humanizing the experiences of our patients.
Ophelia members are not “addicts” or statistics — they’re people. We’re proud to continue telling more in-depth stories about their lives, as we did with Kimberly and Lewis (watch their videos for a glimpse!).
Sources
